세계의 지중해빈혈 시장-시장 점유율, 규모, 동향, 산업 분석 : 치료 유형별, 최종 용도별, 질환 유형별, 지역별, 부문 예측(2022-2030년)

The global thalassemia market size is expected to reach USD 1,492.9 billion by 2030, according to a new study by Polaris Market Research. The report "Thalassemia Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Iron Chelating Drugs, Blood Transfusions, Folic Acid Supplements, Gene Therapy, and Others); By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers driving market growth include rising thalassemia prevalence and increased thalassemia treatment awareness. According to the National Institute Health study report states that as per the Thalassemia International Federation, roughly 7.0% of the world's population suffers from hemoglobin-based diseases and conditions, with approximately 70.0% having sickle cell anemia and the remainder developing thalassemia. Thalassemia affects around 2.1% of the world's population.

Furthermore, as per the Medical Science Study, thalassemia affects roughly 4.4 out of every 10,000 live births worldwide. Since it maintains an autosomal mode of inheritance with no predilection for gender, either males or females receive the relevant gene variants equally. Approximately 5% of the global population possesses a variant in the alpha or beta component of the hemoglobin molecule. Just 1.7% of the world's population has symptoms caused by genetic mutations, which are classified as a thalassemia trait.

However, certain ethnic groups are more prone to be affected, with 5% to 30% of these populations suffering thalassemia indications. Thus, the rising prevalence of the disease has led to an increase in the demand for treatment which is boosting the market growth over the forecast period.

Moreover, the availability of therapies for the treatment of disease with its benefits is boosting the market growth over the forecast period. Chelation therapy and blood transfusions are the most common therapies for thalassemia patients because they are less expensive and more widely available than bone marrow transplants.

Chelation therapy employs medications such as widely prescribed to treat chronic iron overload that occurs following many blood transfusions in people with chronic thalassemia. Chelation therapy medicines used subcutaneously or intravenously using a gradual infusion approach to purify blood improve patients' chances of curing thalassemia. However, the expensive cost of the treatment is a key impediment to market growth.

Thalassemia Market Report Highlights

Blood Transfusions segment is anticipated to grow at a significant CAGR over the forecast period. The expanding market for marrow transplant and blood transfusion therapy, the increasing number of transfusion-dependent patients, and the realization of affordable treatment methods for thalassemia is projected to fuel market expansion.

gene therapy segment accounted for the largest share of the global revenue due to the rise in prevalence of thalassemia disease across the globe.

Asia Pacific is expected to grow at a witness fastest growth over the projected period. The existence of a substantial number of sickle cell disease and thalassemia patients is projected to drive market expansion in the coming years. Supportive government measures targeted at increasing the standard of care provided to individuals with hemoglobinopathies are supporting the region's market growth.

The global market includes ApoPharma Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, IONIS Pharmaceuticals, Kiadis Pharma, La Jolla Pharmaceutical Company, Novartis AG, Pfizer, Inc., SG Pharma Pvt. Lmt., Sangamo Therapeutics, and Vifor Pharma

Polaris Market Research has segmented the Thalassemia market report based on treatment type, disease type, end-user, and region:

Thalassemia, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)

Iron Chelating Drugs

Blood Transfusions

Folic Acid Supplements

Gene Therapy

Others

Thalassemia, Disease Type Outlook (Revenue - USD Billion, 2018 - 2030)

Alpha Thalassemia

Beta Thalassemia

Thalassemia, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital

Research Institute

Others

Thalassemia, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Thalassemia Market Insights

• 4.1. Thalassemia - Industry Snapshot
• 4.2. Thalassemia Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rising Prevalence of Thalassemia
    • 4.2.1.2. Increasing Awareness of Thalassemia Treatment
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Cost of Treatment
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Thalassemia Market Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Thalassemia Market, by Treatment Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
• 5.3. Iron Chelating Drugs
  • 5.3.1. Global Thalassemia Market, by Iron Chelating Drugs, by Region, 2018 - 2030 (USD Billion)
• 5.4. Blood Transfusions
  • 5.4.1. Global Thalassemia Market, by Blood Transfusions, by Region, 2018 - 2030 (USD Billion)
• 5.5. Folic Acid Supplements
  • 5.5.1. Global Thalassemia Market, by Folic Acid Supplements, by Region, 2018 - 2030 (USD Billion)
• 5.6. Gene Therapy
  • 5.6.1. Global Thalassemia Market, by Gene Therapy, by Region, 2018 - 2030 (USD Billion)
• 5.7. Others
  • 5.7.1. Global Thalassemia Market, by Others, by Region, 2018 - 2030 (USD Billion)

6. Global Thalassemia Market, by Disease Type

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
• 6.3. Alpha
  • 6.3.1. Global Thalassemia Market, by Alpha, by Region, 2018 - 2030 (USD Billion)
• 6.4. Beta
  • 6.4.1. Global Thalassemia Market, by Beta, by Region, 2018 - 2030 (USD Billion)

7. Global Thalassemia Market, by End-Use

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
• 7.3. Hospital
  • 7.3.1. Global Thalassemia Market, by Hospital, by Region, 2018 - 2030 (USD Billion)
• 7.4. Research Institute
  • 7.4.1. Global Thalassemia Market, by Research Institute, by Region, 2018 - 2030 (USD Billion)
• 7.5. Others
  • 7.5.1. Global Thalassemia Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Thalassemia Market, by Geography

• 8.1. Key findings
• 8.2. Introduction
  • 8.2.1. Thalassemia Market Assessment, By Geography, 2018 - 2030 (USD Billion)
• 8.3. Thalassemia Market - North America
  • 8.3.1. North America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 8.3.2. North America: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.3.3. North America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.3.4. Thalassemia Market - U.S.
    • 8.3.4.1. U.S.: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.3.4.2. U.S.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.3.4.3. U.S.: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.3.5. Thalassemia Market - Canada
    • 8.3.5.1. Canada: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.3.5.2. Canada.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.3.5.3. Canada: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
• 8.4. Thalassemia Market - Europe
  • 8.4.1. Europe: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 8.4.2. Europe.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.4.3. Europe: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4.4. Thalassemia Market - UK
    • 8.4.4.1. UK: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.4.2. UK.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.4.3. UK: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4.5. Thalassemia Market - France
    • 8.4.5.1. France: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.5.2. France.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.5.3. France: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4.6. Thalassemia Market - Germany
    • 8.4.6.1. Germany: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.6.2. Germany.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.6.3. Germany: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4.7. Thalassemia Market - Italy
    • 8.4.7.1. Italy: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.7.2. Italy.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.7.3. Italy: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4.8. Thalassemia Market - Spain
    • 8.4.8.1. Spain: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.8.2. Spain.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.8.3. Spain: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4.9. Thalassemia Market - Netherlands
    • 8.4.9.1. Netherlands: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.9.2. Netherlands.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.9.3. Netherlands: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4.10. Thalassemia Market - Russia
    • 8.4.10.1. Russia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.10.2. Russia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.10.3. Russia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
• 8.5. Thalassemia Market - Asia Pacific
  • 8.5.1. Asia Pacific: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 8.5.2. Asia Pacific.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.5.3. Asia Pacific: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5.4. Thalassemia Market - China
    • 8.5.4.1. China: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.4.2. China.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.4.3. China: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5.5. Thalassemia Market - India
    • 8.5.5.1. India: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.5.2. India.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.5.3. India: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5.6. Thalassemia Market - Malaysia
    • 8.5.6.1. Malaysia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.6.2. Malaysia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.6.3. Malaysia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5.7. Thalassemia Market - Japan
    • 8.5.7.1. Japan: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.7.2. Japan.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.7.3. Japan: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5.8. Thalassemia Market - Indonesia
    • 8.5.8.1. Indonesia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.8.2. Indonesia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.8.3. Indonesia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5.9. Thalassemia Market - South Korea
    • 8.5.9.1. South Korea: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.9.2. South Korea.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.9.3. South Korea: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
• 8.6. Thalassemia Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 8.6.2. Middle East & Africa.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.6.3. Middle East & Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.6.4. Thalassemia Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.6.4.2. Saudi Arabia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.6.4.3. Saudi Arabia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.6.5. Thalassemia Market - UAE
    • 8.6.5.1. UAE: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.6.5.2. UAE.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.6.5.3. UAE: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.6.6. Thalassemia Market - Israel
    • 8.6.6.1. Israel: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.6.6.2. Israel.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.6.6.3. Israel: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.6.7. Thalassemia Market - South Africa
    • 8.6.7.1. South Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.6.7.2. South Africa.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.6.7.3. South Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
• 8.7. Thalassemia Market - Latin America
  • 8.7.1. Latin America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 8.7.2. Latin America.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.7.3. Latin America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.7.4. Thalassemia Market - Mexico
    • 8.7.4.1. Mexico: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.7.4.2. Mexico.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.7.4.3. Mexico: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.7.5. Thalassemia Market - Brazil
    • 8.7.5.1. Brazil: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.7.5.2. Brazil.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.7.5.3. Brazil: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.7.6. Thalassemia Market - Argentina
    • 8.7.6.1. Argentina: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.7.6.2. Argentina.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.7.6.3. Argentina: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. ApoPharma Inc.
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Acceleron Pharma, Inc.
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. Bluebird Bio Corporation
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Bellicum Pharmaceuticals
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Teva Pharmaceutical Industries Ltd.
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. Fresenius Kabi AG
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. GlaxoSmithKline plc
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. IONIS Pharmaceuticals
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Kiadis Pharma
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Lonza Group Ltd.
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. La Jolla Pharmaceutical Company
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. Novartis AG
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development
• 10.13. Pfizer, Inc.
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Development
• 10.14. SG Pharma Pvt. Lmt.
  • 10.14.1. Company Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Development
• 10.15. Sangamo Therapeutics
  • 10.15.1. Company Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Development
• 10.16. Vifor Pharma
  • 10.16.1. Company Overview
  • 10.16.2. Financial Performance
  • 10.16.3. Product Benchmarking
  • 10.16.4. Recent Development